



RegistryPartners  
**ONCOLOGY**  
D I V I S I O N



1. Understand NAPRC Standards and Requirements for Compliance
2. Understand the Cancer Registrar's role in NAPRC Standard Compliance
3. Review strategies for ensuring your program's survey readiness



Content for this presentation is from the NAPRC  
2017 Edition Manual as well as the 2019  
Commission on Cancer Cluster Conference



Ensures the program and multidisciplinary team is overseen by a qualified Rectal Cancer Program Director



Facility must be accredited by the Commission on Cancer before earning accreditation by the National Accreditation Program for Rectal Cancer.



## Multidisciplinary Rectal Cancer Conference Required Members:

- One appointed physician member from following specialties:
  - Surgery
    - All surgeons (excluding fellows and residents) who perform rectal cancer surgery at the rectal cancer program **must** be a required member
  - Pathology
  - Radiology
  - Medical Oncology
  - Radiation Oncology
- Rectal Cancer Program Director
- Rectal Cancer Program Coordinator - pivotal to ensure everything is done properly



- Alternates can be appointed for required members with the exception of surgery
  - Surgery has no alternates – all surgeons performing rectal cancer surgery must be appointed required members
- **50%** attendance requirement
- Document attendance rate

## Common Problem

- No attendance sheet





- Must meet at least twice each calendar month
- At least one RC-MDT member from each required specialty must attend

## Recommendations:

- Be complete but brief
- Don't bring standards to the group until all needed information is available
- Have a leadership group that meets outside of MDT meetings to discuss standards not related to cancer conference





- Rectal Cancer Program Director is a required member of the RC-MDT
  - Suggest this is a surgeon given their involvement
  - Needs to be someone well respected
- Responsible for evaluating, interpreting, and reporting the RCP's performance through internal audits and NCDB data
- Reports the analysis of NCDB data to the RC-MDT at least **4** times a year
- Reports results of all required Chapter 2 audits to Cancer Committee at least once annually

## Update from NAPRC:

- RCP Director reports on hold due to NCDB infrastructure upgrade
- NAPRC recommends reporting on rectal data from other sources in the interim.



- Provides comprehensive administrative support to RC-MDT
- Ensures pathways are followed according to guidelines set by MDT, including timeliness
- Liaises with relevant departments to ensure all pertinent information is available for RC-MDT meetings
- This is not exclusively a navigation position but a behind-the-scenes position coordinating patient care with health care providers



- All surgeon, pathologist, and radiologist physician members of MDT must complete NAPRC-endorsed education module related to their respective specialties
  - Educational modules on-line
    - Radiology Module is available through the American College of Radiology (ACR)
    - College of American Pathologists' (CAP) – found on CAP's Cancer Protocol Templates website
- **Update from NAPRC:**
  - Currently not rated, surgery modules not yet available



Confirms rectal cancer patients receive appropriate care based on diagnosis and within specified time targets



- Rectal Program must confirm diagnosis of rectal cancer before initiation of treatment
  - If reviewed by a non-MDT member initially it can be reviewed by MDT and an addendum added.
  - If diagnosed elsewhere, pathology slides must be obtained whenever possible and reviewed by a pathology member of the RC-MDT
    - Must track number of slides obtained for patients diagnosed elsewhere
- **95%** of previously undiagnosed, previously untreated rectal cancer patients receive confirmation of diagnosis by biopsy before treatment



- **95%** of all previously untreated rectal cancer patients are staged (systemic and local tumor) before definitive treatment.
- Systemic staging is completed by CT or PET/CT of chest, abdomen, pelvis
- Local tumor staging is completed by MRI of pelvis



- MRI has replaced EUS as primary imaging modality used for local staging of rectal cancer
- Pelvic MRI Requirements
  - **90%** should be read by member of team
  - **95%** have to have staging in reports via synoptic format
  - Suggestion – order for all patients undergoing transanal excision of rectal polyps if suspicious for malignancy
- Recommend re-imaging after therapy
- Must do standardized reporting at each image, even after neoadjuvant treatment

### Common Problem:

- Radiology report not signed by MDT
  - If report gets read by non-MDT and then reviewed by MDT at meeting, they can document an addendum



- CEA Requirements
  - 75% CEA before definitive treatment
    - Difficult to comply with as often gets missed

### Recommendations:

- Before initial visit to surgery, obtain all reports to verify done; if not, surgeon orders
- Order CEA in patients getting transanal excision of rectal polyps
- Have office checklist that coordinator checks





- All rectal cancer patients must have an individualized treatment planning discussion, before initiation of definitive treatment, at a RC-MDT meeting and must include but not limited to:
  - Review of diagnostic and staging studies
  - Assignment of clinical stage
  - Creation of individualized treatment plan
- Emergency patients who do not require a treatment planning discussion:
  - Patients who present with tumor-related complications that require immediate or urgent treatment. Examples include:
    - Rectal tumor perforation
    - Life-threatening tumor hemorrhage
    - Acute large bowel obstruction

## Common Problem

- Tumor board notes but no Treatment Planning Summary



- **50%** of rectal cancer patients must have a standardized treatment evaluation and recommendation summary completed and provided to PCP or referring physician before initiation of definitive treatment. This includes but not limited to:
  - Tumor location in rectum (lower, middle, or upper third)
  - Indication of sphincter involvement
  - Pretreatment (clinical) AJCC stage
  - Pretreatment CRM status (involved, threatened, or not threatened)
  - CEA level
  - Neoadjuvant therapy recommendation
  - Type and duration of neoadjuvant therapy recommended
  - Anticipated date and type of surgical procedure
  - Clinical research study eligibility and/or enrollment

### Common Problem:

- No treatment evaluation and recommendation summary placed in EMR or made available to patient or referring doctor



- **80%** of all previously untreated rectal cancer patients begin definitive treatment within 60 days of diagnosis.
- Standard exceptions:
  - Delays due to documented patient noncompliance or failure of payers to authorize recommended treatment in a timely fashion
- Site should be defined prior to surgery
  - 15 cm from dentate line
  - 17 cm from anal verge



- **80%** of surgical resections are performed by an appointed surgeon member of the RC-MDT.
- **95%** of operative reports for all patients undergoing surgical resection are recorded in a standardized synoptic format
  - Ostrich website and Rectal Registry are available for everyone to be a part of

## Update:

- Synoptic report portion currently not rated
  - Pilot programs ongoing at several hospitals



- **90%** of definitive rectal cancer surgical specimens of primary tumor are read and pathology report completed by an appointed pathologist of the RC-MDT
- **95%** of definitive rectal cancer surgical pathology reports are completed within 2 weeks

### Common Problem:

- Resection specimen not signed by MDT
  - If report gets read by non-MDT and then reviewed by MDT at meeting, they can document an addendum



- Minimum of **65%** of all eligible surgical specimens are photographed to include anterior, posterior, and lateral views and are presented to and discussed by the RC-MDT



- Within 4 weeks of definitive surgical treatment completion, an individualized treatment outcome discussion occurs for all rectal cancer patients at a RC-MDT meeting
- Four primary steps discussion are:
  - Pre-surgical evaluation and treatment
  - Review of outcome of surgery
  - Review of final pathology report and stage
  - Recommendation for adjuvant treatment

### Common Problem:

- Tumor board notes but no Treatment Outcome Summary created



- A standardized treatment summary is provided to at least 50% of all patients within 4 weeks of the MDT Treatment Outcome Discussion.
- A copy is provided to the PCP or referring physician
- This is not a Survivorship Care Plan as defined by std 3.3 for CoC

### Common Problem:

- No treatment outcome summary placed in EMR or made available to patient





- **50%** of all eligible patients who elect to initiate recommended adjuvant therapy regimen begin within 8 weeks of definitive surgical resection



Utilizes data to improve efficiency, standardize care, and improve outcomes



- Std 3.1: RQRS
  - Submit all eligible cases to RQRS
- Std 3.2 Accountability and Quality Improvement Measures
  - Meet expected performance rates



## Update:

- Data submission and quality measures on hold due to NCDB infrastructure upgrade
- Will be rewritten to accommodate new structure



- Identify team (different than MDT)
  - Cancer registry staff
  - Tumor board coordinator
  - Executive director/hospital administrator
  - Administrative assistant
  - Nurse navigator
  - Physician assistant
- Standard Preparation
  - Meet weekly for 3 months to work on/report Standard preparation initially





- Letters of appointment to get approval from medical specialist
  - Keep for documentation
- Policies:
  - Cover all roles and responsibilities: Leadership, RC-MDT, Pre-treatment, Treatment & Quality Improvement
  - Keep as simple as possible
  - Get approval by Cancer Committee
  - Roll out to institution

## Policies Should Include:

- Policy – Rules and Standards
- Process – What, Who, and When
- Procedure – How and Where





- Standards Grid
  - Compliance/what is necessary
  - Action Items
  - Responsible Person
  - Meet weekly for 3 months to report on where things are on the grid
- Attendance with date members joined and left team
  - If both member and alternate come to meeting, this only counts once
- Tumor Conference Grid
- Have an excel spreadsheet with all clinical standards to track compliance
  - Year of evaluation, name, date of birth, date of diagnosis, date pathology returned, etc

# Are you ready to be surveyed?



RegistryPartners

DATA ABSTRACTION / REGISTRY MANAGEMENT / CONSULTING

- Compliant with standards for 12 consecutive months
- Be sure you have strong compliance with commitment to continue
- NAPRC is more flexible, if delays occur due to patient preferences be sure to document these and this will not count against you.
- Contact the CoC to let them know you are ready and request potential dates
- Start preparing (4-6 weeks prior)
  - Make a paper chart for chart review
  - Patient report card (screenshot)
  - Site visit binder



- Start preparing patient charts (4-6 weeks prior)
  - 20 pre-selected adenocarcinoma of rectum
    - If <20, they will review all of your cases
    - 5 cases with adjuvant chemo; these could be part of the 20 cases
    - Categorize charts by diagnosis and treatment at RCP
      - Diagnosed elsewhere and received treatment at RCP
      - Diagnosed and treated elsewhere and surgery at RCP
  - Make a paper chart for chart review for easy navigation/review
    - Mark documents with the respective standard number
    - Include a patient report card at the beginning of each chart including all chapter 2 standards. Sample:



Standards	Compliant	Non-Compliant	Comments
2.1 Review of Diagnostic Pathology			
2.2 Staging before Definitive Treatment			
2.3 Standardized Staging Reporting For MRI Results			
2.4 CEA Level			





- Surveyor Presentation – Value of NAPRC, updates to NCDB, brief overview of pre-site visit evaluation
- Quality Improvement Presentation & Facility Tour – Optional, but encouraged
- Medical Record Review – 3-5 Hours
- Director Meeting – One on One with Surveyor
  - Discussion Points
    - Administrative support
    - Program strength and weaknesses
    - Challenging part of NAPRC launch
    - Special resistance for compliance with standard(s)
- Coordinator Meeting – One on One with Surveyor
  - Discussion Points
    - Most challenging part of complying with requirements?
    - Program strengths and weaknesses
    - What resources you have that are helpful? Resources you need to help achieve requirements?
- Open Discussion – Time to address any questions you have with the surveyor
- Summation